1.Participants either with asymptomatic or who are high risk with COVID-19 as per latest (MOHFW guideline) and as per assertion of investigator own decision at screening and at baseline. <br/ >2.Participants are not suitable for immunoglobulin therapy and history of known IgA deficiency. <br/ >3.Participants with known major illness/organ transplantation/major surgeries during six months before the day of screening. <br/ >4.Participants with more than five days of COVID-19 specific hospitalization prior to treatment at baseline <br/ >5.Confirmed diagnosis of bacterial pneumonia or other active/uncontrolled fungal or viral infections at screening/baseline. <br/ >6.Participants whose ALT/AST levels are 5 times higher than the normal upper limit and total bilirubin is 3 times higher than the upper limit of normal and Creatinine clearance less than 50 mL/min using the Cockcroft-Gault formula. <br/ >7.Participation in other studies and have received investigational intervention 30 days or 5 half-lives (whichever is longer) before the signing the consent. <br/ >

1.Participants either with asymptomatic or who are high risk with COVID-19 as per latest (MOHFW guideline) and as per assertion of investigator own decision at screening and at baseline. <br/ >2.Participants are not suitable for immunoglobulin therapy and history of known IgA deficiency. <br/ >3.Participants with known major illness/organ transplantation/major surgeries during six months before the day of screening. <br/ >4.Participants with more than five days of COVID-19 specific hospitalization prior to treatment at baseline <br/ >5.Confirmed diagnosis of bacterial pneumonia or other active/uncontrolled fungal or viral infections at screening/baseline. <br/ >6.Participants whose ALT/AST levels are 5 times higher than the normal upper limit and total bilirubin is 3 times higher than the upper limit of normal and Creatinine clearance less than 50 mL/min using the Cockcroft-Gault formula. <br/ >7.Participation in other studies and have received investigational intervention 30 days or 5 half-lives (whichever is longer) before the signing the consent. <br/ >

N/A

N/A

1.Participants either with asymptomatic or who are high risk with COVID-19 as per latest (MOHFW guideline) and as per assertion of investigator own decision at screening and at baseline. <br/ >2.Participants are not suitable for immunoglobulin therapy and history of known IgA deficiency. <br/ >3.Participants with known major illness/organ transplantation/major surgeries during six months before the day of screening. <br/ >4.Participants with more than five days of COVID-19 specific hospitalization prior to treatment at baseline <br/ >5.Confirmed diagnosis of bacterial pneumonia or other active/uncontrolled fungal or viral infections at screening/baseline. <br/ >6.Participants whose ALT/AST levels are 5 times higher than the normal upper limit and total bilirubin is 3 times higher than the upper limit of normal and Creatinine clearance less than 50 mL/min using the Cockcroft-Gault formula. <br/ >7.Participation in other studies and have received investigational intervention 30 days or 5 half-lives (whichever is longer) before the signing the consent. <br/ >

1.Participants either with asymptomatic or who are high risk with COVID-19 as per latest (MOHFW guideline) and as per assertion of investigator own decision at screening and at baseline. <br/ >2.Participants are not suitable for immunoglobulin therapy and history of known IgA deficiency. <br/ >3.Participants with known major illness/organ transplantation/major surgeries during six months before the day of screening. <br/ >4.Participants with more than five days of COVID-19 specific hospitalization prior to treatment at baseline <br/ >5.Confirmed diagnosis of bacterial pneumonia or other active/uncontrolled fungal or viral infections at screening/baseline. <br/ >6.Participants whose ALT/AST levels are 5 times higher than the normal upper limit and total bilirubin is 3 times higher than the upper limit of normal and Creatinine clearance less than 50 mL/min using the Cockcroft-Gault formula. <br/ >7.Participation in other studies and have received investigational intervention 30 days or 5 half-lives (whichever is longer) before the signing the consent. <br/ >